Ladiratuzumab vedotin | Antibody-Drug Conjugate inhibitor | Read Reviews & Product Use Citations

Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas.

CAS No.

Click to purchase products related to Ladiratuzumab vedotin

Purity & Quality Control

Batch: D405701 Purity: 99.15% Protein concentration: 3.21mg/ml Endotoxin Level: ＜1EU/mg

99.15

Choose Selective Antibody-Drug Conjugate Inhibitors

Biological Activity

Description	Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas.

References
[1] McGuinness JE, et al. Expert Opin Biol Ther. 2021 Jul;21(7):903-913.

References

[1] McGuinness JE, et al. Expert Opin Biol Ther. 2021 Jul;21(7):903-913.

Product Details

DAR	4.16
ADC antiody	ladiratuzumab
ADC linker	A proteolytically cleavable type linker
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field